Noguchi Tsuyoshi, Sato Tetsuro, Takeno Shinsuke, Uchida Yuzo, Kashima Kenji, Yokoyama Shigeo, Müller Wolfram
Department of Oncological Science (Surgery II), Oita Medical University, Hasama-machi, Oita, Japan.
Oncol Rep. 2002 Nov-Dec;9(6):1277-82.
The biological behaviour of a gastrointestinal stromal tumor (GIST) cannot be easily predicted from preoperative clinical examination alone. As a result, there is little standardization in the surgical treatment of GIST. In this study, we analyzed the clinicopathology and immunohistochemistry of 20 cases of GIST to clarify factors associated with tumors showing malignant potential. Immunohistochemical analysis of KIT, CD34, vimentin, alpha-smooth muscle actin (SMA), s-100, p53, ki-67, bcl-2 and bax expression was performed on 20 surgically resected GIST. An apoptotic index (AI) was calculated for each sample using a TdT-mediated dUTP-biotin nick end-labeling method. With regard to bcl-2, t(14;18) translocations were also investigated using a polymerase chain reaction based method. Finally, the relationship between these biological results and clinicopathological data was analyzed. Of the 20 cases studied, two patients died due to lung or liver metastasis. All cases stained positive for vimentin, nine cases were positive for alpha-SMA and three cases positive for s-100. All cases were stained for both KIT and CD34, which tended to correlate with malignant potential. There was significant difference in frequency of bcl-2 overexpression (p<0.05) and trend in Ki-67 labeling index (p=0.098) between benign and malignant cases. However, with regard to bcl-2, no chromosomal t(14;18) translocations were detected in four analyzed cases. In GIST, overexpression of bcl-2 may play an important role in increasing malignant potential. Furthermore, Ki-67 L.I. and bcl-2 overexpression may be useful in predicting malignant potential, and therefore help to determine the surgical treatment, follow-up manner, and the necessity of adjuvant therapy.
仅通过术前临床检查很难轻易预测胃肠道间质瘤(GIST)的生物学行为。因此,GIST的外科治疗几乎没有标准化。在本研究中,我们分析了20例GIST的临床病理及免疫组化情况,以明确与具有恶性潜能肿瘤相关的因素。对20例手术切除的GIST进行了KIT、CD34、波形蛋白、α平滑肌肌动蛋白(SMA)、S-100、p53、Ki-67、bcl-2和bax表达的免疫组化分析。使用TdT介导的dUTP生物素缺口末端标记法计算每个样本的凋亡指数(AI)。关于bcl-2,还采用基于聚合酶链反应的方法研究了t(14;18)易位情况。最后,分析了这些生物学结果与临床病理数据之间的关系。在所研究的20例病例中,2例患者因肺或肝转移死亡。所有病例波形蛋白染色均呈阳性,9例α-SMA阳性,3例S-100阳性。所有病例KIT和CD34均染色,其往往与恶性潜能相关。良性和恶性病例之间bcl-2过表达频率存在显著差异(p<0.05),Ki-67标记指数有变化趋势(p=0.098)。然而,关于bcl-2,在4例分析病例中未检测到染色体t(14;18)易位。在GIST中,bcl-2过表达可能在增加恶性潜能方面起重要作用。此外,Ki-67 LI和bcl-2过表达可能有助于预测恶性潜能,从而有助于确定手术治疗、随访方式及辅助治疗的必要性。